Eikon Therapeutics (NASDAQ:EIKN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Eikon Therapeutics (NASDAQ:EIKN – Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Other equities research analysts have also recently issued research reports about the company. Mizuho upgraded Eikon Therapeutics to a “strong-buy” rating in a report on Wednesday, September 16th. Weiss Ratings raised Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Monday, August 3rd. Wedbush dropped their target price on Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating for the company in a research note on Friday, August 14th. HC Wainwright assumed coverage on Eikon Therapeutics in a research note on Friday, October 16th. They issued a “buy” rating and a $23.00 target price for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Eikon Therapeutics in a research report on Friday, August 21st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

Get Our Latest Stock Report on EIKN

Eikon Therapeutics Trading Down 9.9%

Shares of NASDAQ:EIKN opened at $5.39 on Friday. The business’s fifty day moving average price is $7.42 and its two-hundred day moving average price is $10.02. Eikon Therapeutics has a one year low of $5.01 and a one year high of $17.40.

Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($1.59) earnings per share for the quarter, topping the consensus estimate of ($1.74) by $0.15. As a group, sell-side analysts expect that Eikon Therapeutics will post -7.04 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Eikon Therapeutics news, major shareholder Group Iv Gp Lp Column purchased 89,200 shares of Eikon Therapeutics stock in a transaction that occurred on Thursday, September 3rd. The stock was purchased at an average price of $11.56 per share, with a total value of $1,031,152.00. Following the completion of the acquisition, the insider owned 89,200 shares of the company’s stock, valued at approximately $1,031,152. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Hedge Funds Weigh In On Eikon Therapeutics

A number of hedge funds have recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Eikon Therapeutics by 29.0% during the second quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock valued at $55,873,000 after purchasing an additional 962,046 shares in the last quarter. Regents of The University of California acquired a new stake in Eikon Therapeutics in the third quarter worth about $5,106,000. State Street Corp acquired a new stake in Eikon Therapeutics in the second quarter worth about $4,621,000. Parkman Healthcare Partners LLC acquired a new stake in Eikon Therapeutics in the second quarter worth about $3,341,000. Finally, Goldman Sachs Group Inc. bought a new position in Eikon Therapeutics in the 3rd quarter valued at about $1,028,000.

Eikon Therapeutics Company Profile

(Get Free Report)

Eikon Therapeutics is a biopharmaceutical company focused on discovering and developing medicines for serious diseases, including cancer. The company uses advanced imaging, computational biology and drug-discovery methods to study how proteins behave in living cells and identify potential therapeutic targets. Founded in 2019 by Roger Perlmutter, a former head of Merck Research Laboratories, Eikon is based in California. Its work is centered on research and development; the company is not known for marketed medicines.

Further Reading

Analyst Recommendations for Eikon Therapeutics (NASDAQ:EIKN)

Receive News & Ratings for Eikon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eikon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.